Marksans Pharma gets EIR from US FDA for its Goa facility

EIR is issued to a company detailing inspectional findings

Marksans Pharma has received Establishment Inspection Report (EIR) from the US health regulator for its Goa facility.

The company has received EIR from the United States Food and Drug Administration (USFDA) after inspection of its Goa facility from April 3-7, 2017, Marksans Pharma said in a BSE filing.

As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.